1-(cyclopropylcarbonyl)-1,4-diazepane(SALTDATA: FREE)
|
- $45 - $496.09
- Product name: 1-(cyclopropylcarbonyl)-1,4-diazepane(SALTDATA: FREE)
- CAS: 926237-53-8
- MF: C9H16N2O
- MW: 168.24
- EINECS:
- MDL Number:MFCD09048004
- Synonyms:1-(cyclopropylcarbonyl)-1,4-diazepane(SALTDATA: FREE);1-cyclopropanecarbonyl-1,4-diazepane;Methanone, cyclopropyl(hexahydro-1H-1,4-diazepin-1-yl)-
4 prices
Selected condition：
Brand
- AK Scientific
- American Custom Chemicals Corporation
- TRC
Package
- 5MG
- 10mg
- 50mg
- 250mg
- ManufacturerAK Scientific
- Product number0923CX
- Product descriptionCyclopropyl(1,4-diazepan-1-yl)methanone
- Packaging250mg
- Price$332
- Updated2021-12-16
- Buy
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0371423
- Product description1-(CYCLOPROPYLCARBONYL)-1,4-DIAZEPANE 95.00%
- Packaging5MG
- Price$496.09
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB427543
- Product description1-cyclopropanecarbonyl-1,4-diazepane
- Packaging50mg
- Price$65
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB427543
- Product description1-cyclopropanecarbonyl-1,4-diazepane
- Packaging10mg
- Price$45
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 0923CX | Cyclopropyl(1,4-diazepan-1-yl)methanone | 250mg | $332 | 2021-12-16 | Buy |
| American Custom Chemicals Corporation | CHM0371423 | 1-(CYCLOPROPYLCARBONYL)-1,4-DIAZEPANE 95.00% | 5MG | $496.09 | 2021-12-16 | Buy |
| TRC | B427543 | 1-cyclopropanecarbonyl-1,4-diazepane | 50mg | $65 | 2021-12-16 | Buy |
| TRC | B427543 | 1-cyclopropanecarbonyl-1,4-diazepane | 10mg | $45 | 2021-12-16 | Buy |
Properties
Boiling point :320.2±35.0 °C(Predicted)
Density :1.108±0.06 g/cm3(Predicted)
pka :10.18±0.20(Predicted)
Density :1.108±0.06 g/cm3(Predicted)
pka :10.18±0.20(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|